Arndt Justus Georg Schottelius
Directeur/Bestuurslid bij GUBRA A/S
Vermogen: 407 685 $ op 30-04-2024
Actieve functies van Arndt Justus Georg Schottelius
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
GUBRA A/S | Directeur/Bestuurslid | 01-01-2022 | - |
Independent Dir/Board Member | 01-01-2022 | - | |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | Algemeen Directeur | 01-03-2024 | - |
Loopbaan van Arndt Justus Georg Schottelius
Eerdere bekende functies van Arndt Justus Georg Schottelius
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
AFFIMED N.V. | Hoofd Techniek/Wetenschap/O&O | 01-04-2020 | 29-02-2024 |
MORPHOSYS AG | Corporate Officer/Principal | - | 01-03-2017 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Hoofd Techniek/Wetenschap/O&O | 01-05-2017 | - |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Hoofd Techniek/Wetenschap/O&O | - | - |
Opleiding van Arndt Justus Georg Schottelius
University of Freiburg | Doctorate Degree |
Statistieken
Internationaal
Duitsland | 4 |
Verenigd Koninkrijk | 3 |
Verenigde Staten | 2 |
Operationeel
Chief Tech/Sci/R&D Officer | 3 |
Corporate Officer/Principal | 1 |
Doctorate Degree | 1 |
Sectoraal
Health Technology | 6 |
Consumer Services | 2 |
Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
MORPHOSYS AG | Health Technology |
AFFIMED N.V. | Health Technology |
GUBRA A/S | Commercial Services |
Bedrijven in privébezit | 3 |
---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | Health Technology |